We are live on
!
Find out more
CM
Crestline Management Portfolio holdings
AUM
$46.3M
1-Year Est. Return
48.82%
This Fund
S&P 500
This Quarter
Est. Return
+31.44%
1 Year Est. Return
+48.82%
3 Year Est. Return
+52.52%
5 Year Est. Return
+37.91%
10 Year Est. Return
+316.44%
AUM
$719M
AUM Growth
-$27.1M
(-3.6%)
Cap. Flow
-$214M
Cap. Flow
% of AUM
-29.71%
Top 10 Holdings %
Top 10 Hldgs %
66.29%
Holding
201
New
72
Increased
18
Reduced
27
Closed
81
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Travelers Companies
TRV
|
+$7.93M |
| 2 |
FNB Corp
FNB
|
+$7.61M |
| 3 |
Sherwin-Williams
SHW
|
+$7.06M |
| 4 |
Allstate
ALL
|
+$5.58M |
| 5 |
Willis Towers Watson
WTW
|
+$5.57M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JUNO
Juno Therapeutics, Inc.
JUNO
|
+$274M |
| 2 |
Celanese
CE
|
+$6.41M |
| 3 |
MON
Monsanto Co
MON
|
+$6.27M |
| 4 |
Bunge Global
BG
|
+$5.97M |
| 5 |
Air Products & Chemicals
APD
|
+$4.65M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 19.98% |
| 2 | Industrials | 5.93% |
| 3 | Healthcare | 5.67% |
| 4 | Technology | 4.78% |
| 5 | Communication Services | 1.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CMA
26
DELISTED
Comerica
CMA
| $3.58M | 0.5% |
+47,000
| New | +$3.37M |
|
27
Truist Financial
TFC
$63.3B
| $3.57M | 0.5% |
76,000
+14,000
| +23% | +$644K |
|
|
MSCC
28
DELISTED
Microsemi Corp
MSCC
| $3.55M | 0.49% |
+68,943
| New | +$3.47M |
|
|
DISH
29
DELISTED
DISH Network Corp.
DISH
| $3.52M | 0.49% |
+64,973
| New | +$3.84M |
|
30
Franklin Resources
BEN
$17.6B
| $3.51M | 0.49% |
+78,918
| New | +$3.46M |
|
31
Biogen
BIIB
$30B
| $3.49M | 0.49% |
11,145
+1,602
| +17% | +$474K |
|
32
Western Digital
WDC
$188B
| $3.46M | 0.48% |
+52,976
| New | +$3.52M |
|
33
Union Pacific
UNP
$174B
| $3.36M | 0.47% |
+29,000
| New | +$3.11M |
|
34
Primerica
PRI
$9.98B
| $3.36M | 0.47% |
41,188
+26,768
| +186% | +$2.09M |
|
|
TRUE
35
DELISTED
TrueCar
TRUE
| $3.21M | 0.45% |
+203,325
| New | +$3.63M |
|
36
Global Payments
GPN
$23B
| $3.15M | 0.44% |
+33,161
| New | +$3.12M |
|
|
DNB
37
DELISTED
Dun & Bradstreet
DNB
| $3.02M | 0.42% |
25,933
-16,720
| -39% | -$1.86M |
|
38
Goldman Sachs
GS
$300B
| $2.92M | 0.41% |
+12,321
| New | +$2.78M |
|
39
Hexcel
HXL
$7.79B
| $2.87M | 0.4% |
+50,000
| New | +$2.69M |
|
40
Thomson Reuters
TRI
$42.8B
| $2.87M | 0.4% |
+53,822
| New | +$2.87M |
|
41
Everest Group
EG
$14.5B
| $2.85M | 0.4% |
+12,479
| New | +$3.15M |
|
42
Southwest Airlines
LUV
$22B
| $2.8M | 0.39% |
50,000
-2,000
| -4% | -$112K |
|
43
DXC Technology
DXC
$1.82B
| $2.76M | 0.38% |
+37,179
| New | +$2.64M |
|
44
Prudential Financial
PRU
$42.4B
| $2.74M | 0.38% |
+25,793
| New | +$2.76M |
|
45
Ionis Pharmaceuticals
IONS
$8.6B
| $2.58M | 0.36% |
+50,957
| New | +$2.67M |
|
46
Bristol-Myers Squibb
BMY
$133B
| $2.58M | 0.36% |
+40,400
| New | +$2.36M |
|
|
PBCT
47
DELISTED
People's United Financial Inc
PBCT
| $2.54M | 0.35% |
140,000
-35,000
| -20% | -$604K |
|
48
S&P Global
SPGI
$121B
| $2.54M | 0.35% |
+16,233
| New | +$2.47M |
|
49
UMB Financial
UMBF
$11.1B
| $2.53M | 0.35% |
+34,000
| New | +$2.38M |
|
50
8x8 Inc
EGHT
$269M
| $2.53M | 0.35% |
+187,341
| New | +$2.55M |
|
Similar funds
MCMC
RRC
PCM
NPCM
FCM
EGI
IPHI
SM
Crestline Management's Q3 2017 Portfolio in Review
As of Q3 2017, Crestline Management held 201 positions worth $719M, down 3.6% from $746M the previous quarter. Its ten largest holdings account for 66% of the portfolio.
Crestline Management withdrew a net $214M in Q3 2017, closing 81 positions and reducing 27 holdings. Its most notable exit was Celanese, an estimated $6.41M position sold in full.
By sector, the portfolio is most concentrated in Financials at 20% of assets, up from 13% a quarter earlier, followed by Industrials and Healthcare.
Against the trend, Crestline Management opened a new position in Travelers Companies worth $7.78M.
- Crestline Management's largest Q3 2017 buy was Travelers Companies: 63,503 shares worth $7.78M.
- Crestline Management added most to FNB Corp in Q3 2017, an estimated $7.61M increase.
- Crestline Management's biggest Q3 2017 reduction was Juno Therapeutics, Inc., cutting an estimated $274M.
- Crestline Management fully exited Celanese in Q3 2017, selling an estimated $6.41M.
- Crestline Management's ten largest holdings make up 66% of its $719M portfolio in Q3 2017.
- Crestline Management opened 72 new positions and closed 81 in Q3 2017.
- Crestline Management's portfolio value fell 3.6% quarter-over-quarter to $719M.
Based on Crestline Management's 13F filing for Q3 2017, filed 14 Nov 2017.